vTv Therapeutics Inc. (NASDAQ:VTVT) Sees Significant Decline in Short Interest

vTv Therapeutics Inc. (NASDAQ:VTVT) was the target of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 24,100 shares, a decline of 13.6% from the February 13th total of 27,900 shares. Based on an average daily volume of 13,300 shares, the short-interest ratio is currently 1.8 days. Approximately 1.6% of the company’s shares are sold short.

Wall Street Analyst Weigh In

Several research firms have weighed in on VTVT. Alliance Global Partners began coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 price target for the company. StockNews.com began coverage on shares of vTv Therapeutics in a research report on Wednesday. They issued a “sell” rating on the stock.

vTv Therapeutics Trading Down 7.7 %

VTVT stock opened at $20.99 on Wednesday. The firm’s 50-day moving average price is $16.76 and its two-hundred day moving average price is $15.40. vTv Therapeutics has a 12-month low of $12.12 and a 12-month high of $30.99. The stock has a market capitalization of $66.96 million, a price-to-earnings ratio of -4.63 and a beta of 1.07.

Hedge Funds Weigh In On vTv Therapeutics

Hedge funds have recently modified their holdings of the company. JPMorgan Chase & Co. purchased a new position in shares of vTv Therapeutics in the fourth quarter valued at about $25,000. Geode Capital Management LLC increased its position in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 1,327 shares during the period. Finally, FMR LLC purchased a new position in shares of vTv Therapeutics during the third quarter valued at about $2,402,000. Hedge funds and other institutional investors own 17.51% of the company’s stock.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.